Nicolas Barzoukas’ practice is devoted to intellectual property litigation, including patent, trade secret, and trade dress litigation. He concentrates on patent litigation in the pharmaceutical field. He has also litigated in industries related to chemistry, electronics, biotechnology, medical devices, lasers and mechanical systems. In 2001, the Texas Lawyer recognized him as one of 40 “up-and-comers” in the Texas legal community. Mr. Barzoukas was recognized in Chambers USA - America’s Leading Lawyers for Business 2005 - 2013 in the field of Patent Litigation in Texas.
His representations in Hatch-Waxman Act patent infringement suits have resulted in the protection of the franchises for blockbuster pharmaceutical products, such as FOSAMAX®, FOSAMAX® OW, VASOTEC®, PEPCID®, ACTONEL®, and VIOXX®. In addition, Mr. Barzoukas successfully challenged the U.S. Patent and Trademark Office’s rule denying the application of Hatch-Waxman Act patent term restoration to patents receiving a new, 20-year, patent term established by the Uruguay Round Agreements Act.
Mr. Barzoukas participates in all aspects of litigation, from initial case development, to trial, to appellate representation. Specifically, he is involved in all aspects of discovery, hearings, witness preparation and presentation, trials and appeals. Mr. Barzoukas’ practice, in addition to Hatch-Waxman Act lawsuits, has involved suits challenging the interpretation of the patent statute by federal agencies, and the constitutionality of certain provisions of the patent statute.
In addition to litigation matters, Mr. Barzoukas also counsels clients on intellectual property enforcement matters, defensive and offensive litigation strategy, freedom to operate, settlement negotiations and licensing. He has also directed complex prosecution matters involving the reexamination or reissue proceedings of asserted patents.
Mr. Barzoukas has also authored “Teaching Old Drugs New Tricks” in the August/September 2000 issue of IP Worldwide, and “Pill Splitting Raises Issues of Safety and Patent Coverage” in the May 22, 2000 issue of the National Law Journal.